| Quarter | Prior | Estimate | Actual | Surprise | |
|---|---|---|---|---|---|
| Q4 2021 After-Hours | EPS: REV: | ||||
| Q3 2021 After-Hours | EPS: REV: | 0.37 656.692M | |||
| Q2 2021 After-Hours | EPS: REV: | ||||
| Q1 2021 After-Hours | EPS: REV: | -0.25 1.126B | |||
| Q4 2020 After-Hours | EPS: REV: | -0.26 943.947M | 0.27 740.24M | 0.41 788.952M | 51.85% 6.58% |
| Q3 2020 After-Hours | EPS: REV: | -0.12 745.208M | 0.12 572.18M | 0.37 656.692M | 208.33% 14.77% |
| Q2 2020 After-Hours | EPS: REV: | -0.14 599.578M | -0.48 615.92M | -0.38 768.352M | 20.83% 24.75% |
| Q1 2020 After-Hours | EPS: REV: | -0.02 454.104M | -0.38 1.02B | -0.25 1.126B | 34.21% 10.39% |
| Q4 2019 After-Hours | EPS: REV: | 0.01 365.335M | -0.30 809.85M | -0.26 943.947M | 13.33% 16.56% |
| Q3 2019 After-Hours | EPS: REV: | 0.18 343.094M | -0.22 714.01M | -0.12 745.208M | 45.45% 4.37% |
Data powered by Benzinga Pro Calendars - Start your FREE TRIAL today!
News Coverage
- DraftKings Analysts Cheer Strong Q4, Sports Betting Growth And SBTech Integration
- Nio Reports Wider Q4 Loss Despite Revenues Topping $1B
- Travere Therapeutics: Q4 Earnings Insights
- Arcturus Therapeutics: Q4 Earnings Insights
- Hanger: Q4 Earnings Insights
- Recap: Xenon Pharmaceuticals Q4 Earnings
- Helios Technologies: Q4 Earnings Insights
- NIO: Q4 Earnings Insights
- Recap: Viela Bio Q4 Earnings
- Recap: FS KKR Capital Q4 Earnings
